DUX4 and facioscapulohumeral muscular dystrophy: Oligonucleotide- and CRISPR-based approaches have demonstrated the feasibility of DUX4 knockdown in reversing muscle-specific FSHD pathology, with promising preliminary results in vitro and in vivo.